dc.contributor.author |
Grabowski, Henry |
|
dc.contributor.author |
Lewis, Tracy |
|
dc.contributor.author |
Guha, Rahul |
|
dc.contributor.author |
Ivanova, Zoya |
|
dc.contributor.author |
Salgado, Maria |
|
dc.contributor.author |
Woodhouse, Sally |
|
dc.coverage.spatial |
United States |
|
dc.date.accessioned |
2016-09-13T07:35:23Z |
|
dc.date.issued |
2012 |
|
dc.identifier |
http://www.ncbi.nlm.nih.gov/pubmed/24624656 |
|
dc.identifier.issn |
1064-590X |
|
dc.identifier.uri |
https://hdl.handle.net/10161/12743 |
|
dc.description.abstract |
This article examines how the nature of competition between brands in a therapeutic
category changes after generic entry and provide a framework for analyzing the effect
of generic entry on consumer welfare that takes into account the generic free riding
problem. It demonstrates that changes in competition along dimensions other than retail
price--such as competition in research and development efforts and in promotional
activities--may, in certain situations, result in generic entry having an overall
negative impact on consumer welfare.
|
|
dc.language |
eng |
|
dc.relation.ispartof |
Food Drug Law J |
|
dc.subject |
Consumer Advocacy |
|
dc.subject |
Drug Costs |
|
dc.subject |
Drugs, Generic |
|
dc.subject |
Economic Competition |
|
dc.subject |
Humans |
|
dc.subject |
United States |
|
dc.title |
Does generic entry always increase consumer welfare? |
|
dc.type |
Journal article |
|
duke.contributor.id |
Grabowski, Henry|0099498 |
|
duke.contributor.id |
Lewis, Tracy|0288071 |
|
pubs.author-url |
http://www.ncbi.nlm.nih.gov/pubmed/24624656 |
|
pubs.begin-page |
373 |
|
pubs.end-page |
ii |
|
pubs.issue |
3 |
|
pubs.organisational-group |
Duke |
|
pubs.organisational-group |
Economics |
|
pubs.organisational-group |
Fuqua School of Business |
|
pubs.organisational-group |
Trinity College of Arts & Sciences |
|
pubs.publication-status |
Published |
|
pubs.volume |
67 |
|